Sino-US artificial intelligence (AI) firm XtalPi Inc. has announced a strategic partnership agreement with China-based CK Life Sciences (HKG: 0775). The collaboration aims to leverage AI and clinical diagnosis data, including biomarker information from cancer patients and healthy populations, to develop molecular diagnostic models that predict cancer prognosis risk based on miRNA. Financial details of the agreement have not been disclosed.
Combining AI and Clinical Data for Cancer Prognosis
XtalPi Inc., known for its advanced AI capabilities, and CK Life Sciences, a leading life sciences company, will work together to create diagnostic models that can predict the prognosis of cancer patients. By integrating AI with clinical and biomarker data, the partnership seeks to enhance the accuracy of cancer risk assessments and provide personalized treatment strategies.
Building on a Previous Partnership
This is not the first collaboration between XtalPi Inc. and CK Life Sciences. At the end of 2022, the two companies paired up to develop an AI-enabled cancer vaccine research and development platform. This new partnership builds on their previous efforts, showcasing a continued commitment to leveraging AI technology in the field of oncology.-Fineline Info & Tech
